-billion as first agent in the new class of DPP IV inhibitors.

-billion as first agent in the new class of DPP – IV inhibitors, Merck’s Januvia the way in the growth of type-2 – diabetes market by $ 12 run in 2005 to over $ 18 billion in 2013. Google can provide peak – year sales for Januvia.

Wong attended MIT and Williams College and earned MMSc. Degrees from Harvard University.. – How Januvia may profound impact profound impact on the practice of medicine for type 2 diabetes by delaying the progression of the disease.Donny Wong, a research analyst at Decision Resources, where he analyzes pharmaceutical markets for metabolic disorders such as obesity, type 2 diabetes, metabolic syndrome and osteoporosis. He has more than 12 years experience in scientific research and has co-authored nine peer-reviewed articles and book reviews.Was about 30 % of patients, of the cancer have an diagnoses at the time the cancer, by of the lungs with the most common site of spreading spread. Surgery on kidney cell carcinoma that has not spread often medicinal and is therefore a major treat option particularly since this kind of cancer not responding well to chemo or irradiation, explains Dr. Leibovich. Importance Mayo research.. Mayo Clinic study Mayo Clinic study from 888 RCC, explains Dr. Patients who have. Complete removal of all tumors was spread out on average five years to survive In comparison the patients had that do not have any of metastases remotely one year cancers – specific survival. The results of are encouraging and RCC is difficult to heal if it spread to other organs.

Collaboration and assistanceOther scientists are Angela alto, MD, Stephen Boorjian, MD, Christina Lohse and Michael Blood, MD Their the Mayo Foundation the Mayo Foundation for Medical Education and Research.

Is a the type of care. Not surgical removal of of metastasized tumors – patient at the treatment category pan from 888: 506 or 57 percent – median of cancer-specific survival: 1.1 years.